Century Therapeutics, Inc. (IPSC) stock
IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.65+0.02 (+1.23%)
Close on Nov 13, 2026Market cap $298.77MP/E –Yield –
Century Therapeutics cash
Cash and short-term investments held at the end of each period.
Century Therapeutics's cash was $117.20M at Sep 30, 2026. For fiscal 2025 it was $117.11M, down 39.0% from the year before. The highest annual figure on record is $317.48M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $117.11M | -39.0% |
| FY2024 | Dec 31, 2024 | $192.06M | +9.9% |
| FY2023 | Dec 31, 2023 | $174.72M | -45.0% |
| FY2022 | Dec 31, 2022 | $317.48M | +41.4% |
| FY2021 | Dec 31, 2021 | $224.60M | +194.5% |
| FY2020 | Dec 31, 2020 | $76.27M | +73.1% |
| FY2019 | Dec 31, 2019 | $44.06M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $117.20M | -13.8% |
| Q2 FY2026 | Jun 30, 2026 | $119.71M | -24.5% |
| Q1 FY2026 | Mar 31, 2026 | $134.80M | -19.7% |
| Q4 FY2025 | Dec 31, 2025 | $117.11M | -39.0% |
| Q3 FY2025 | Sep 30, 2025 | $135.91M | -32.4% |
| Q2 FY2025 | Jun 30, 2025 | $158.55M | -20.4% |
| Q1 FY2025 | Mar 31, 2025 | $167.90M | -13.5% |
| Q4 FY2024 | Dec 31, 2024 | $192.06M | +9.9% |
| Q3 FY2024 | Sep 30, 2024 | $200.95M | +17.2% |
| Q2 FY2024 | Jun 30, 2024 | $199.24M | +25.8% |
| Q1 FY2024 | Mar 31, 2024 | $194.00M | -23.5% |
| Q4 FY2023 | Dec 31, 2023 | $174.72M | -45.0% |
| Q3 FY2023 | Sep 30, 2023 | $171.48M | -52.1% |
| Q2 FY2023 | Jun 30, 2023 | $158.38M | -58.4% |
| Q1 FY2023 | Mar 31, 2023 | $253.45M | -30.1% |
| Q4 FY2022 | Dec 31, 2022 | $317.48M | +41.4% |
| Q3 FY2022 | Sep 30, 2022 | $357.84M | +20.5% |
| Q2 FY2022 | Jun 30, 2022 | $380.74M | -4.8% |
| Q1 FY2022 | Mar 31, 2022 | $362.74M | +353.4% |
| Q4 FY2021 | Dec 31, 2021 | $224.60M | +194.5% |
| Q3 FY2021 | Sep 30, 2021 | $296.87M | +1156.4% |
| Q2 FY2021 | Jun 30, 2021 | $399.80M | +1655.3% |
| Q1 FY2021 | Mar 31, 2021 | $80.00M | +81.6% |
| Q4 FY2020 | Dec 31, 2020 | $76.27M | – |
| Q3 FY2020 | Sep 30, 2020 | $23.63M | – |
| Q2 FY2020 | Jun 30, 2020 | $22.78M | – |
| Q4 FY2019 | Dec 31, 2019 | $44.06M | – |
See a number that looks wrong?